News Search Results
May 01, 2025, 08:18 ET Everads Announces Five Abstracts Accepted for Presentation at ARVO 2025, Including First-in-Human Results Using its Novel Suprachoroidal Injector
Israel, May 1, 2025 /PRNewswire/ -- Everads Therapy, a clinical-stage biotechnology company advancing suprachoroidal delivery of therapeutics for targeted, office-based treatment of diseases affecting the back of the eye, today
More news about: Everads Therapy
May 01, 2025, 08:00 ET Sapience Therapeutics Announces Oral Presentation at the Upcoming 2025 American Society of Clinical Oncology (ASCO) Annual Meeting Featuring Lucicebtide Phase 2 Results
N.Y., May 1, 2025 /PRNewswire/ -- Sapience Therapeutics, Inc., a clinical-stage biotechnology company focused on the discovery and development of peptide therapeutics to address oncogenic and immune dysregulation that drive cancer, today
More news about: Sapience Therapeutics, Inc.
May 01, 2025, 08:00 ET AmacaThera and Merck Animal Health Announce Collaboration in Animal Health
TORONTO, May 1, 2025 /PRNewswire/ - AmacaThera, a clinical-stage biotechnology company specializing in drug delivery, announced it has signed a binding evaluation and option agreement with Merck Animal Health to develop long-acting
More news about: AmacaThera Inc.
May 01, 2025, 07:00 ET Armata Pharmaceuticals Receives $4.65 Million of Additional Non-Dilutive Award Funding from the U.S. Department of Defense to Support Ongoing diSArm Clinical Trial of AP-SA02
May 1, 2025 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat
More news about: Armata Pharmaceuticals, Inc.
May 01, 2025, 07:00 ET Scinai Immunotherapeutics and Pincell to Host Webinar on a Blockbuster Drug Candidate for Devastating Rare Skin Diseases
treatments and better management strategies to improve patient outcomes and reduce mortality rates. About Pincell srl PinCell is a biotechnology company targeting a novel pathological pathway to develop first-in-class anti-inflammatory therapies for the treatment of rare, severe and highly
More news about: Scinai Immunotherapeutics Ltd.
May 01, 2025, 06:45 ET Lilly reports first-quarter 2025 financial results and highlights pipeline momentum
life-changing discoveries for nearly 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges:
More news about: Eli Lilly and Company
May 01, 2025, 05:45 ET Contact The Gross Law Firm by May 20, 2025 Deadline to Join Class Action Against Sana Biotechnology, Inc.(SANA)
May 1, 2025 /PRNewswire/ --The Gross Law Firm issues the following notice to shareholders of Sana Biotechnology, Inc. (NASDAQ: SANA).
More news about: The Gross Law Firm
May 01, 2025, 04:00 ET S&E bio Receives Korea's First Approval for Exosome-Based Therapy Clinical Trial
May 1, 2025 /PRNewswire/ -- S&E bio Co., Ltd., a biotechnology company specializing in exosomal microRNA-based therapies, has received approval from Korea's Ministry of Food and Drug Safety (MFDS) to initiate
More news about: S&E bio Co., Ltd.
May 01, 2025, 03:00 ET Blue Earth Therapeutics initiates Phase 2 Clinical Trial evaluating the efficacy and safety of Lutetium (177Lu) rhPSMA-10.1 Injection in metastatic castrate resistant prostate cancer
financing round in 2024. With proven management expertise across the spectrum of radiopharmaceutical and oncology drug development, as well as biotechnology start–up experience, the Company aims to innovate and improve upon current technologies and rapidly advance new targeted therapies for serious diseases.
More news about: Blue Earth Therapeutics Ltd
Apr 30, 2025, 17:51 ET RoosterBio Announces Collaboration with Thermo Fisher Scientific to Advance Cell and Exosome Therapy Manufacturing
Fisher. "We're excited to work with the team to expand our Contract Development Manufacturing Organization (CDMO) services and support our biotechnology partners through the research and optimization, process development and manufacturing of critical treatments." Consistent with global best
More news about: RoosterBio, Inc.
Apr 30, 2025, 16:05 ET REGENXBIO to Host Conference Call on May 12 to Discuss First Quarter 2025 Financial Results and Recent Operational Highlights
Those who plan on participating are advised to join 15 minutes prior to the start time. ABOUT REGENXBIO Inc.REGENXBIO is a biotechnology company on a mission to improve lives through the curative potential of gene therapy. Since its founding in 2009, REGENXBIO has pioneered the field
More news about: REGENXBIO Inc.
Apr 30, 2025, 16:00 ET Rgenta Therapeutics Announces Presentation of Preclinical Data from Proprietary RSwitch Technology at the American Society of Gene And Cell Therapy (ASGCT) 2025 Annual Meeting
Mass., April 30, 2025 /PRNewswire/ -- Rgenta Therapeutics, a clinical-stage biotechnology company pioneering the development of a new class of oral small molecules targeting RNA and RNA regulation for oncology and neurological disorders,
More news about: Rgenta Therapeutics
Apr 30, 2025, 15:17 ET Fluorescence Microscopy Market to Reach $1.3 Billion by 2029
targeted therapies. Understanding Cellular Processes: Real-time observation of cellular mechanisms helps in medical research and biotechnology advances. Research Funding: Increased funding supports new technologies, equipment, and researcher training. Miniaturization:
More news about: BCC Research LLC
Apr 30, 2025, 10:30 ET Surface Disinfectant Market worth US$4.38 billion by 2030 with 7.6% CAGR | MarketsandMarkets™
on end user, the surface disinfectant market is segmented into hospitals, clinics, and ASCs, diagnostic laboratories, pharmaceutical & biotechnology companies, and research laboratories. The hospitals, clinics, and ASCs segment is expected to grow at the fastest CAGR during the forecast period.
More news about: MarketsandMarkets
Apr 30, 2025, 09:05 ET Dalen Meeter Joins Aspen Neuroscience as Chief Financial Officer
DIEGO, April 30, 2025 /PRNewswire/ -- Aspen Neuroscience, Inc., a private biotechnology company developing personalized, autologous cell therapies, has appointed Dalen Meeter, CPA, MBA, as Chief Financial
More news about: Aspen Neuroscience, Inc.
Apr 30, 2025, 08:33 ET Ingenium Therapeutics Receives FDA Feedback Enabling Direct Phase 2 Trial for Gengleucel in MRD+ AML
Ingenium Therapeutics, a clinical-stage biotechnology company advancing allogeneic natural killer (NK) cell therapies, today announced that it has received positive regulatory feedback from the U.S.
More news about: Ingenium Therapeutics
Apr 30, 2025, 08:05 ET INOVIO to Present at Upcoming Scientific and Investor Conferences
MEETING, Pa., April 30, 2025 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious
More news about: INOVIO Pharmaceuticals, Inc.
Apr 30, 2025, 08:00 ET Anixa Biosciences to Present at the H.C. Wainwright 3rd Annual BioConnect Investor Conference on May 20th
Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced its participation in the H.C. Wainwright 3rd Annual BioConnect Investor
More news about: Anixa Biosciences, Inc.
Apr 30, 2025, 08:00 ET CellFE® Partners with DKFZ and TcellTech to Advance DNA Vector Genetic Engineering for Cellular Therapies
www.cellfebiotech.com. About TcellTech TCellTech GmbH is a clinical-stage biotechnology company founded in 2022 as a spin-out from the German Cancer Research Center (DKFZ) and is focused on developing universal, personalized adoptive
More news about: CellFE
Apr 30, 2025, 07:30 ET Apertura Gene Therapy and Rett Syndrome Research Trust Collaborate to Pioneer Advanced Genetic Medicines for Rett Syndrome Using TfR1-Targeted AAV Capsid
Conn., April 30, 2025 /PRNewswire/ -- Apertura Gene Therapy, a biotechnology company focused on innovative gene therapy solutions, and the Rett Syndrome Research Trust (RSRT), an organization working to cure Rett Syndrome,
More news about: Apertura Gene Therapy
Apr 30, 2025, 07:30 ET Immunic Announces Vidofludimus Calcium Reduced Risk of Disability Worsening by 30% in Primary Progressive Multiple Sclerosis Patients from Phase 2 CALLIPER Trial
Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today
More news about: Immunic, Inc.
Apr 30, 2025, 07:00 ET Avista Therapeutics Announces Oral Presentation at Association for Research in Vision and Ophthalmology 2025 Annual Meeting
Avista Therapeutics, a pre-clinical-stage biotechnology company developing innovative gene therapies for rare ophthalmic conditions, today announced that the Company will present data highlighting the
More news about: Avista Therapeutics
Apr 30, 2025, 06:59 ET Q32 Bio Announces FDA Fast Track Designation Granted to Bempikibart (ADX-914) for the Treatment of Alopecia Areata
April 30, 2025 /PRNewswire/ -- Q32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing innovative therapies for alopecia areata (AA) and other autoimmune and inflammatory diseases, today announced that
More news about: Q32 Bio
Apr 30, 2025, 03:11 ET Genocury Biotech Announces Groundbreaking Advance in Relapsed/Refractory DLBCL Through Pioneering In Vivo CD19 CAR-T Therapy
approach." About Genocury Biotech Shenzhen Genocury Biotech Co., Ltd. is a clinical-stage biotechnology pioneer redefining in vivo cell engineering through its proprietary Vivoexpress™ platform. This modular delivery system enables targeted delivery
More news about: Genocury Biotech
Apr 29, 2025, 14:06 ET NEUVOGEN Announces Poster Presentation at the American Association of Cancer Research Annual Meeting
29, 2025 /PRNewswire/ -- NEUVOGEN, Inc. ("NEUVOGEN THERAPEUTICS" or "NEUVOGEN"), a San Diego based biotechnology company, will present data that its next generation whole tumor cell vaccine (NGEN-143) activates T cells that recognize a diverse antigen repertoire.
More news about: NEUVOGEN, Inc.